Aspira Women’s Health to Announce Year End 2022 Financial Results and Host Conference Call on March 22, 2023
March 03, 2023 08:38 ET AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced that the company will report its financial results for the year ended December 31, 2022 after the market closes on Wednesday, March 22, 2023.…
Aspira Women’s Health Announces National Payer Coverage for OvaWatch
First National Payer to Cover OvaWatch March 03, 2023 08:00 ET AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced that one of the nation’s top national health insurance companies with over 80 million lives worldwide has agreed…
Aspira Women’s Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary Results in Line with Cash Utilization Guidance, and Other Highlights
January 09, 2023 16:05 ET Preliminary testing volume during the fourth quarter of 2022 was 5,643, an increase of 18 % compared to the fourth quarter of 2021 Preliminary results consistent with previously provided cash utilization guidance for the fourth quarter and full year of 2022 Further reduced staff to achieve anticipated year-over-year salary cost…
Aspira Women’s Health Announces Publication of Real-World Data Validating Use of OvaWatch for the Management of Adnexal Masses
January 06, 2023 08:00 ET Provides clinical validation for the use of OvaWatchSM in the assessment of ovarian cancer risk for suspected benign or indeterminate adnexal masses Paper published in the peer-reviewed journal, Frontiers in Medicine AUSTIN, Texas, Jan. 06, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company…
Aspira Women’s Health Announces Three Reimbursement Milestones that Improve Patient Access to its OvaSuite SM Testing Portfolio
December 27, 2022 08:00 ET Expanded Medicare coverage for multi-marker testing, including Ova1Plus® and OvaWatchSM, through the 2023 Omnibus Spending Bill Granted a new PLA Code for OvaWatch by the American Medical Association Expanded Medicaid coverage adding another 5 states: Virginia, Alabama, Maine, Pennsylvania, and Rhode Island AUSTIN, Texas, Dec. 27, 2022 (GLOBE NEWSWIRE) —…
Aspira Women’s Health Announces the Commercial Launch of OvaWatch(SM)
November 29, 2022 16:01 ET AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, announced the commercial launch of OvaWatchSM, a new non-invasive blood-based test for the assessment of ovarian cancer risk in women with adnexal masses. OvaWatch is part of…
Aspira Women’s Health Reports Third Quarter 2022 Financial Results
November 10, 2022 07:00 ET Increased year-over-year product revenue by 26% to $2.0 million and year-over-year product volume by 29% to 5,524 units Reconfirmed fourth quarter launch of OvaWatch ovarian cancer risk assessment and announced rebranding of the ovarian cancer product portfolio as OvaSuite Executed and fully funded a sponsored research agreement with Harvard’s Dana…
Aspira Women’s Health to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10
November 01, 2022 08:00 ET AUSTIN, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that the company will report its financial results for the third quarter ended September 30, 2022 before the market open on Thursday, November 10, 2022. Management will also host…
Aspira Women’s Health to Participate at the Upcoming MicroCap Rodeo Windy City Roundup 2022
October 06, 2022 16:05 ET AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will present and be available for 1×1 meetings at the MicroCap Rodeo Presents Windy City Roundup 2022 conference taking place in-person on October 12-13, 2022 in Chicago,…
Aspira Women’s Health Announces Formal Launch of Co-Marketing and Distribution Collaboration with BioReference
OVA1Plus® now available to an expanded network of physicians, supporting patients nationwide October 05, 2022 08:00 ET AUSTIN, Texas, Oct. 05, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the formal launch of its co-marketing and distribution collaboration with BioReference®, an OPKO…
Aspira Women’s Health Announces Publication of its Second-Generation MultiVariate Index Assay, OVERA®, in the Detection of Cancer in Filipino Women
Data demonstrates the accuracy of Aspira’s multivariate assessment test OVERA in a non-White population and concludes use of OVERA to be better than CA-125 in detecting early-stage cancer in women with a pelvic mass September 12, 2022 16:28 ET AUSTIN, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based…
Aspira Women’s Health Inc. Announces Pricing of $9.0 Million Public Offering
August 23, 2022 08:00 ET AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the pricing of the previously announced underwritten public offering of 12,000,000 shares of its common stock and warrants to purchase an aggregate of…
Aspira Women’s Health Inc. Announces Proposed Public Offering
August 22, 2022 16:02 ET AUSTIN, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. The…
Aspira Women’s Health Hosting Women’s Health Webinar on Ovarian Cancer Risk Assessments Utilizing Multivariate Index Assay
KOL Event to take place on Wednesday, August 24th at 12:00pm ET August 18, 2022 16:05 ET AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced that it will host a key opinion leader (KOL) webinar on women’s health…
Aspira Women’s Health Reports Second Quarter 2022 Financial Results
August 10, 2022 07:30 ET Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units Entered into a research agreement with Harvard’s Dana Farber Cancer Institute, Brigham & Women’s Hospital, and Medical University of Lodz for development of a diagnostic test for endometriosis Reduced cash utilization by $3.9 Million…
Aspira Women’s Health to Announce Second Quarter 2022 Financial Results and Host Conference Call on Wednesday, August 10
August 01, 2022 08:00 ET AUSTIN, Texas, Aug. 01, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced that the company will report its financial results for the second quarter ended June 30, 2022 before the market open on Wednesday, August 10, 2022.…
Aspira Women’s Health Announces Appointment of Two New Board Members
Seasoned Directors further strengthen Board with decades of industry and leadership experience June 23, 2022 16:05 ET AUSTIN, Texas, June 23, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the appointments of two seasoned Board members: Dr. Robert Auerbach and Ms. Ruby Sharma. Dr
Aspira Women’s Health Announces Publication of Paper Validating OvaWatch™ Algorithm in the Detection of Ovarian Cancer
Paper published in the June online issue of JCO Clinical Cancer Informatics June 16, 2022 16:01 ET AUSTIN, Texas, June 16, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the online publication of a paper validating its OvaWatch™ algorithm in the detection of…
Aspira Women’s Health to Participate in the Upcoming Investor Conferences
AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will participate in the “MicroCap Rodeo Spring Into Action Best Ideas” Conference virtually and the “William Blair 42nd Annual Growth Stock Conference” in Chicago. Details for both investor conferences are below: William…
Aspira Women’s Health Reports First Quarter 2022 Financial Results
May 11, 2022 07:30 ET Product Revenue Increased 30% to $1.8 million; OVA1plus Volume Grew 28% to 4,819 Units New Ordering Physicians in the First Quarter Grew 47% to 603 Year Over Year Board and Leadership appointments announced Conference Call and Webcast scheduled for today, May 11th at 8:30 a.m. ET AUSTIN, Texas, May 11,…
Aspira Women’s Health Reports Fourth Quarter and Full Year 2021 Financial Results
Total Revenue Increased 46% to $6.8 million; OVA1 Volume Grew 28% to 17,359 Units Exercise of option in the Harvard Dana-Farber Cancer Institute Collaboration Leadership and Board appointments implemented in First Quarter of 2022 Conference Call and Webcast scheduled for today, March 23rd at 8:30 a.m. ET AUSTIN, Texas —March 23, 2022 — Aspira Women’s…
Aspira Women's Health to Announce Year End 2021 Financial Results and Host Conference Call on Wednesday, March 23rd
AUSTIN, Texas —March 15, 2022 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that the company will report its financial results for the year ended December 31, 2021 before the market open on Wednesday, March 23, 2022. Management will also host a conference call with investors to discuss financial…
Aspira Women’s Health Announces Appointment of Celeste Fralick, Ph.D., to its Board of Directors
AUSTIN, Texas —Feb. 28, 2022 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced the appointment of Celeste Fralick, Ph.D., to its Board of Directors, effective February 23, 2022. Dr. Fralick is an accomplished executive with over four decades of data strategy experience. She brings to the Board a broad…
Valerie Palmieri Elevated to Executive Chair of the Board; Nicole Sandford Appointed President and CEO
Expanded leadership team to drive strategic partnerships, accelerate new commercial launches, and grow overall enterprise value AUSTIN, Texas —February 25, 2022 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today named Valerie Palmieri as Executive Chair of the Board, and Nicole Sandford as President and CEO of the Company. Jim LaFrance,…
Aspira Women’s Health, Inc. Expands Senior Leadership Team with Addition of Mr. Michael Newton as Head of Sales and Marketing
AUSTIN, Texas — February 22, 2022 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company today announced the appointment of Mr. Michael Newton as Head of Sales and Marketing who brings to the company over twenty years of experience in the diagnostic healthcare area. In this role, Mr. Newton will be responsible…